Please note

Due to the recent spike in Covid-19 cases, we are no longer able to entertain walk-in visits to our headquarters or any of our facilities.

DRM powder for infusion

Dexa Medica

Ingredients in every vial

Doripenem 500 mg

Each package contains

1 vial of 500 mg

Dosage form

Powder for infusion

Dosage formPowder for Infusion

Flavour

None

W.H.O. classification

J01D
J01D

A.T.C. Level 1

Anatomical Main group

J - Antiinfectives for systemic use
J01D

A.T.C. Level 2

Therapeutic subgroup

J01 - Antibacterials for Systemic Use
J01D

A.T.C. Level 3

Pharmacological subgroup

J01D - Other Beta-Lactam Antibacterials in ATC

Available in

Indonesia

Warnings

Alcohol

CONSULT YOUR DOCTORSafety of this item for use with alcohol has not been established. Please consult your doctor.

Machinery

CONSULT YOUR DOCTORSafety of this item for use while operating heavy machinery has not been established. Please consult your doctor.

Pregnancy

NOT RECOMMENDEDThis item is not safe for use during pregnancy.

Lactation

CONSULT YOUR DOCTORSafety of this item for use during lactation has not been established. Please consult your doctor.

Indication

Doripenem is indicated for the treatment of the following infections in adults:
Nosocomial pneumonia
(including ventilator-associated pneumonia)
Complicated intra-abdominal infections
Consideration should be given to official guidance on the appropriate use of antibacterial agents.

Dosage

18 YEARS OLD AND ABOVE
Recommended dosage and administration by infection:
— Nosocomial pneumonia (including ventilator-associated pneumonia):
500 mg every 8 hours for 1 or 4 hours.

— Complicated intra-abdominal infection:
500 mg every 8 hours for 1 hour.

0 TO 18 YEARS OLD
Not recommended

65 YEARS OLD AND ABOVE
No dosage adjustment is necessary in elderly patients, except in cases of moderate to severe renal insufficiency.

METHOD OF ADMINISTRATION
The usual treatment duration of doripenem therapy ranges from 5-14 days and should be guided by the severity, site of the infection, and the patient's clinical response.

Doripenem is to be reconstituted and then further diluted prior to administration by intravenous infusion over a period of 1 or 4 hours.

PATIENT WITH RENAL IMPAIRMENT
In patients with mild renal impairment (i.e., creatinine clearance (CrCl) is 51-79 ml/minute), no dose adjustment is necessary. In patients with moderate renal impairment (CrCl 30 to <50 ml/minute), the dose of doripenem should be 250 mg every 8 hours. In patients with severe renal impairment (CrCl <30 ml/minute), the dose of doripenem should be 250 mg every 12 hours.

PATIENT WITH HEPATIC IMPAIRMENT
No dose adjustment is necessary.